Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response.

Dose modifications for concomitant strong CYP3A inhibitors, moderate/severe hepatic impairment, severe renal impairment, hematologic and non-hematologic toxicities: see full labeling. ALCL or IMT ...